Wednesday, August 26, 2026

Tonight's bar looks clearable: Life Sciences guidance was just raised, Facet brings a recurring-revenue stream, and Mobile Solutions is at record margins. The real story is whether Industrial margin pressure from A&D and power-gen is peaking and whether the portfolio review signals a shift toward higher-margin, less cyclical mix. A good quarter beats estimates; a great one would show Industrial margins inflecting and Life Sciences growth extending into the FY27 guide.

The bar should be clearable: record backlog, 29.8% revenue growth, 93.2% EBITDA growth, and raised guidance provide a strong cushion for tonight's print. The real story is whether long-haul fiber demand is beginning to inflect and whether Building Systems can maintain high-teens margins while absorbing NTI. A good quarter would be a beat with steady guide; a great quarter would show NTI closing, BEAD starting, and management raising the long-haul TAM/revenue ramp profile.

The Q3 guidance range of $207–215M sets a modest bar against the $210M just reported, so tonight is more about the trajectory than the print. The real story is whether high-end IC re-accelerates from ~$56M and margin pressure starts to ease; a good quarter could deliver an in-line print with confirmation that tape-outs are normalizing, while a great one might show high-end IC tracking back toward the ~$71M record and the U.S./Korea expansion milestones holding.

The bar is essentially undefined because CHRN has not disclosed a revenue or EBITDA baseline for the AI business; tonight's 'beat' is less important than whether management gives that baseline. The real story is whether the merged entity can show contracted demand and a credible funding path for AI compute capacity. A good quarter closes the merger cleanly and shows the stub is contained; a great one validates the ~$1.6B contribution assumption with multi-year contracted revenue or capacity commitments.

The bar looks clearable: Q2 already delivered EDA growth >8%, IP +12% sequentially, an $11.0B backlog, and raised FY26 guidance, while confirmed competitors point to strong AI-driven demand. The narrative-changing evidence would be early revenue from Ansys/multiphysics fusion and new IP/agentic monetization layering on top of volume growth. A good quarter likely beats and holds guidance; a great one would show Design IP reaccelerating and backlog/order intake turning back up.

The bar looks clearable: Q4 guidance is $29–33M revenue and $0.03–0.05 non-GAAP EPS, with drone FY26 tracking to $10–14M and OEM count above 15. The real story tonight is whether the drone ramp is converting into a durable FY27 growth line—double-digit total revenue growth and 15–20% drone mix are the markers. A good quarter clears guidance; a great one adds MediaTek design wins, Red Cat expansion detail, and non-GAAP gross margin stability around 43.6%.

Q2 delivered 6.3% core growth and management raised FY26 core growth to 4.5%–6.0%, so the bar looks clearable for tonight. The real story is whether AI becomes a visible demand driver and whether Advanced Therapeutics’ mid-teens growth commitment is backed by order momentum. A good quarter holds or raises guidance; a great one shows CDMO capacity is filling up and AI partnerships are extending the replacement cycle.

The bar is likely clearable: Data Center grew 92% YoY, ACIE is accelerating, FCF hit a record $49B, and confirmed ecosystem reads from AMZN and ARM point to continued AI infrastructure demand. The real story tonight is whether the ACIE/sovereign wave broadens and whether Vera Rubin stays on schedule, not just whether revenue beats. A good quarter clears elevated estimates; a great one would show demand remains supply-constrained and that the Vera Rubin ramp is on or ahead of plan with no new export-control shock.

The near-term bar likely clears if HPQ maintains its FY26 EPS and FCF framework, especially after Q2 EPS and FCF both beat. The narrative hinges on whether AI PC mix accelerates toward 60-70% for FY2027 and whether Print margin can be confirmed recovering to the mid-to-high teens. A good quarter holds guidance; a great one shows AI PC acceleration plus credible Print margin recovery — enough to support a re-rating from the current 6.2x EV/EBITDA multiple.

The bar should be clearable: FY27 guidance implies ~19% revenue growth from a base that already produced $1.058B in Q4 (+20% YoY), with RPO growth at +40%, ARR at $1.9B (+16% YoY), and a record 21.3% operating margin in Q4. The real story tonight is whether accelerating AI-driven product demand from EXA/hyperscale can offset the industry-wide component-cost drag that cut product gross margin to 67.3% in Q4. A good quarter clears revenue and operating profit; a great one shows EXA pipeline conversion, hyperscale linearity, and product margin clawback happening simultaneously.

With trailing revenue growth at 13.0%, EBITDA growth near 55%, and the EV/EBITDA multiple already down to 33.6x, the bar for tonight likely centers on execution rather than valuation. The core story remains VMware displacement, so a beat on revenue/ARR plus confirmation of new-logo momentum should clear. A great quarter would layer in tangible product milestones — Pure/Dell GA status and AI production wins — to extend the narrative beyond displacement.